Association between adherence to an antimicrobial stewardship program and mortality among hospitalised cancer patients with febrile neutropaenia: a prospective cohort study

BMC Infectious Diseases

Rodrigo P dos Santos²  Luciano Z Goldani¹  Regis G Rosa³ 

[1] Section of Infectious Diseases, Hospital de Clínicas de Porto Alegre, Ramiro Barcelos, 2350, Room 2225, PO Box 90035–903, Porto Alegre, RS, Brazil;Infection Control Committee of Hospital de Clínicas, Porto Alegre, Brazil;Postgraduate Program in Medical Sciences of Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

关键词: Mortality;    Adherence;    Program evaluation;    Chemotherapy;    Antimicrobial agents;    Febrile neutropenia;   

Others  :  1127721
DOI  :  10.1186/1471-2334-14-286

 received in 2013-04-19, accepted in 2014-05-15,  发布年份 2014

【 摘 要 】

Background

Initial management of chemotherapy-induced febrile neutropaenia (FN) comprises empirical therapy with a broad-spectrum antimicrobial. Currently, there is sufficient evidence to indicate which antibiotic regimen should be administered initially. However, no randomized trial has evaluated whether adherence to an antimicrobial stewardship program (ASP) results in lower rates of mortality in this setting. The present study sought to assess the association between adherence to an ASP and mortality among hospitalised cancer patients with FN.

Methods

We conducted a prospective cohort study in a single tertiary hospital from October 2009 to August 2011. All adult patients who were admitted to the haematology ward with cancer and FN were followed up for 28 days. ASP adherence to the initial antimicrobial prescription was determined. The mortality rates of patients who were treated with antibiotics according to the ASP protocol were compared with those of patients treated with other antibiotic regimens. The multivariate Cox proportional hazards model and propensity score were used to estimate 28-day mortality risk.

Results

A total of 307 FN episodes in 169 subjects were evaluated. The rate of adherence to the ASP was 53%. In a Cox regression analysis, adjusted for propensity scores and other potential confounding factors, ASP adherence was independently associated with lower mortality (hazard ratio, 0.36; 95% confidence interval, 0.14–0.92).

Conclusions

Antimicrobial selection is important for the initial management of patients with FN, and adherence to the ASP, which calls for the rational use of antibiotics, was associated with lower mortality rates in this setting.

【 授权许可】

   
2014 Rosa et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Schimpff S, Satterlee W, Young VM, Serpick A: Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971, 284:1061-1065.
• [2]The EORTC International Antimicrobial Therapy Cooperative Group: Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987, 317:1662-1698.
• [3]Sickles EA, Greene WH, Wiernick PH: Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 1975, 135:715-719.
• [4]Freifeld AG, Bow EJ, Sepkowitz KA, Beockh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011, 52:e56-e93.
• [5]De Naurois J, Novitzky-Basso I, Gill MJ, Marti Marti F, Cullen MH, Roila F: Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol 2010, 21:v252-v256.
• [6]MacDougall C, Polk RE: Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev 2005, 18:638-656.
• [7]Paterson DL: The role of antimicrobial management programs in optimizing antibiotic prescribing within hospitals. Clin Infect Dis 2006, 53:S23-S28.
• [8]Montassier E, Batard E, Gastinne T, Potel G, de La Cochetière MF: Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis 2013, 32(7):841-850.
• [9]Carling P, Fung T, Killion A, Terrin N, Barza M: Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol 2003, 24:699-706.
• [10]White AC Jr, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB: Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997, 25:230-239.
• [11]Fishman N: Antimicrobial stewardship. Am J Med 2006, 34:S55-S63. discussion S64-S73
• [12]Valiquette L, Cossette B, Garant MP, Diab H, Pepin J: Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007, 45:S112-S121.
• [13]Davey P, Brown E, Fenelon L, Finch R, Gould IM, Homes A, Ramsey C, Taylor E, Wiffen P, Wilcox M: Systematic review of antimicrobial drug prescribing in hospitals. Emerg Infect Dis 2006, 12:211-216.
• [14]Lipworth AD, Hyle EP, Fishman NO, Nachamkin I, Bilker WB, Marr AM, Larosa LA, Kasbekar N, Lautenbach E: Limiting the emergence of extended-spectrum Beta-lactamase-producing enterobacteriaceae: influence of patient population characteristics on the response to antimicrobial formulary interventions. Infect Control Hosp Epidemiol 2006, 27:279-286.
• [15]Davey P, Brown E, Charani E, Fenelon L, Gould IM, Holmes A, Ramsey CR, Wiffen PJ, Wilcox M: Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2013, 4:CD003543.
• [16]Ohl CA, Ashley ESD: Antimicrobial stewardship programs in community hospitals: the evidence base and case studies. Clin Infect Dis 2011, 53:S23-S28.
• [17]Zuckermann J, Moreira LB, Stoll P, Moreira LM, Kuchenbecker RS, Polanczyk CA: Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes. Ann Hematol 2008, 87:139-145.
• [18]Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002, 34(6):730-751.
• [19]Dos Santos RP, Nagel F, Gastal SL, Sander GB, Jacobi TS, Konkewicz LR, Kuplich NM, Lovatto CG, Pires MR, Aronis ML, Ribeiro SP: Antimicrobial stewardship program Hospital de Clinicas de Porto Alegre, 2010 Infection Control Committee. Rev HCPA 2010, 30:13-21.
• [20]Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J: The Multinational Association for Supportive Care in Cancer Risk Index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000, 18:3038-3051.
• [21]Clinical and Laboratory Standards Institute (CLSI): Performance Standards for Antimicrobial Susceptibility Testing: Twenty-second Informational Supplement. Wayne, PA: CLSI; 2012:M100-S22.
• [22]Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH: Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006, 106:2258-2266.
• [23]Jin J, Lee YM, Ding Y, Koh LP, Lim SE, Lim R, Tambyah PA, Hsu LY: Prospective audit of febrile neutropenia management at a tertiary university hospital in Singapore. Ann Acad Med Singapore 2010, 39:453-599.
• [24]Rimawi RH, Mazer MA, Siraj DS, Gooch M, Cook PP: Impact of regular collaboration between infectious diseases and critical care practitioners on antimicrobial utilization and patient outcome. Crit Care Med 2013, 41(9):2099-2107.
• [25]Kaki R, Elligsen M, Walker S, Simor A, Palmay L, Daneman N: Impact of antimicrobial stewardship in critical care: a systematic review. J Antimicrob Chemother 2011, 66(6):1223-1230.